Efficacy of CALLG2008 protocol in treatment of adult acute lymphoblastic leukemia: a single center analysis.
10.7534/j.issn.1009-2137.2013.04.014
- Author:
Xiao-Zhu YANG
1
,
2
;
Ting-Bo LIU
;
Jing ZHENG
;
Bu-Yuan CHEN
;
Xin-Ji CHEN
;
Xiao-Yun ZHENG
;
Jing LI
;
Jian-Da HU
Author Information
1. Department of Hematology, Union Clinical Medical College, Union Hospital, Fujian Medical University
2. Fujian Institute of Hematology, Fuzhou 350001, Fujian Province, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Antineoplastic Combined Chemotherapy Protocols;
therapeutic use;
Female;
Humans;
Male;
Middle Aged;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
drug therapy;
Retrospective Studies;
Treatment Outcome;
Young Adult
- From:
Journal of Experimental Hematology
2013;21(4):886-890
- CountryChina
- Language:Chinese
-
Abstract:
CALLG2008 Protocol is sequential chemotherapy for adult acute lymphoblastic leukemia (ALL) established by Collaborative Group of adults acute lymphoblastic leukemia. It is emphasized that comprehensive treatment of adult ALL according to risk stratification is rather important. This study was purposed to evaluate the therapeutic efficacy of CALLG2008 for adult ALL. The clinical data of adult ALL patients of ≥ 14 years old diagnosed and treated by CALLG2008 Protocol were collected from May 1, 2009 to December 31, 2011 in Fujian Medical University Union Hospital, and the efficacy was analyzed. The results showed that 31 out of 33 cases of ALL achieved CR, the CR rate was up to 93.9%, the PR rate was 3.1%, and the total response rate was 97%. There were no uncontrolled severe toxicities, and no early deaths were observed. The overall survival (OS) at 1 year was only 66.7%,the relapse rate was 43.8% and the 1-year mortality was 33.3 %. This may be related with no-enough compliance, no-enough economical support and short follow-up time of the patients. The risk factor analysis showed that WBC level in newly diagnosed patients may influence the OS and relapse-free survival (RFS) of ALL. It is concluded that CALLG2008 protocol applied to adult ALL has a high remission quality and low mortality rate during the induction. The disease free survival (DFS) needs to be observed longer. It is essential to carry out MRD monitoring to determine the early recurrence and improving the long-term efficacy.
